The Neoangiogenic Transcriptomic Signature Impacts Hepatocellular Carcinoma Prognosis and Can Be Triggered by Transarterial Chemoembolization Treatment.

MLA

Critelli, Rosina Maria, et al. “The Neoangiogenic Transcriptomic Signature Impacts Hepatocellular Carcinoma Prognosis and Can Be Triggered by Transarterial Chemoembolization Treatment.” Cancers, vol. 16, no. 20, Oct. 2024. EBSCOhost, https://doi.org/10.3390/cancers16203549.

APA

Critelli, R. M., Casari, F., Borghi, A., Serino, G., Caporali, C., Magistri, P., Pecchi, A., Shahini, E., Milosa, F., Di Marco, L., Pivetti, A., Lasagni, S., Schepis, F., De Maria, N., Dituri, F., Martínez-Chantar, M. L., Di Benedetto, F., Giannelli, G., & Villa, E. (2024). The Neoangiogenic Transcriptomic Signature Impacts Hepatocellular Carcinoma Prognosis and Can Be Triggered by Transarterial Chemoembolization Treatment. Cancers, 16(20). https://doi.org/10.3390/cancers16203549

Chicago

Critelli, Rosina Maria, Federico Casari, Alberto Borghi, Grazia Serino, Cristian Caporali, Paolo Magistri, Annarita Pecchi, et al. 2024. “The Neoangiogenic Transcriptomic Signature Impacts Hepatocellular Carcinoma Prognosis and Can Be Triggered by Transarterial Chemoembolization Treatment.” Cancers 16 (20). doi:10.3390/cancers16203549.